(4S)-4-(methoxymethyl)-1,3-oxazolidin-2-one | 1453082-75-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (4S)-4-(methoxymethyl)-1,3-oxazolidin-2-one
• 英文别名: (S)-4-Methoxymethyl-oxazolidin-2-one
• CAS: 1453082-75-1
• 化学式: C₅H₉NO₃
• 分子量: 131.131
• InChiKey: PQNDPDPSBMIYMC-BYPYZUCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-吗啉基-4,6-二氯嘧啶 、 (4S)-4-(methoxymethyl)-1,3-oxazolidin-2-one 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.33h， 生成 (S)-3-(6-chloro-2-(morpholin-4-yl)pyrimidin-4-yl)-4-(methoxymethyl)oxazolidin-2-one
  参考文献：
  名称：

  OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF

  摘要：

  本发明涉及氧唑烷-2-酮取代嘧啶化合物，其作为PI3K（磷脂酰肌醇-3-激酶）抑制剂，以及其药物组合物、制备方法和用于治疗依赖于PI3K的疾病、病症和疾病的用途。

  公开号：

  US20130225574A1
• 作为产物：
  描述：

  tert-butyl (S)-(1-hydroxy-3-methoxypropan-2-yl)carbamate 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以94%的产率得到(4S)-4-(methoxymethyl)-1,3-oxazolidin-2-one
  参考文献：
  名称：

  COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS

  摘要：

  化合物的结构式（I），其药学上可接受的盐，以及利用该结构式（I）化合物治疗细菌感染的用途被披露。

  公开号：

  US20140206677A1

文献信息

• Oxazolidin-2-one compounds and uses thereof
  申请人：Novartis AG

  公开号：US08865894B2

  公开（公告）日：2014-10-21

  The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

  本发明涉及氧杂环丙烷-2-酮取代嘧啶化合物，其作为PI3K（磷脂酰肌醇-3-激酶）抑制剂，以及其制药组合物、制造方法和用于治疗依赖于PI3K的病症、疾病和障碍的用途。
• Compounds and methods for treating bacterial infections
  申请人：AstraZeneca AB

  公开号：US08889671B2

  公开（公告）日：2014-11-18

  Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed.

  公开了式（I）的化合物，其药学上可接受的盐，以及使用式（I）的化合物治疗细菌感染的用途。
• Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)
  作者：Gregory S. Basarab、Peter Doig、Vincent Galullo、Gunther Kern、Amy Kimzey、Amy Kutschke、Joseph P. Newman、Marshall Morningstar、John Mueller、Linda Otterson、Karthick Vishwanathan、Fei Zhou、Madhusudhan Gowravaram

  DOI：10.1021/acs.jmedchem.5b00863

  日期：2015.8.13

  A novel class of bacterial type-II topoisomerase inhibitor displaying a spiropyrimidinetrione architecture fused to a benzisoxazole scaffold shows potent activity against Grampositive and fastidious Gram-negative bacteria. Here, we describe a series of N-linked oxazolidinone substituents on the benzisoxazole that improve upon the antibacterial activity of initially described compounds of the class, show favorable PK properties, and demonstrate efficacy in an in vivo Staphylococcus aureus infection model. Inhibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-positive and a Gram-negative organisms was demonstrated. Compounds showed a clean in vitro toxicity profile, including no genotoxicity and no bone marrow toxicity at the highest evaluated concentrations or other issues that have been problematic for some fluoroquinolones. Compound lu was identified for advancement into human clinical trials for treatment of uncomplicated gonorrhea based on a variety of beneficial attributes including the potent activity and the favorable safety profile.
• COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
  申请人：AstraZeneca AB

  公开号：US20140206677A1

  公开（公告）日：2014-07-24

  Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed.

  化合物的结构式（I），其药学上可接受的盐，以及利用该结构式（I）化合物治疗细菌感染的用途被披露。
• OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF
  申请人：Novartis AG

  公开号：US20130225574A1

  公开（公告）日：2013-08-29

  The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

  本发明涉及氧唑烷-2-酮取代嘧啶化合物，其作为PI3K（磷脂酰肌醇-3-激酶）抑制剂，以及其药物组合物、制备方法和用于治疗依赖于PI3K的疾病、病症和疾病的用途。